BioNTech Faces Regulatory Hurdle as Key Vaccine Study Halts

FDA's stricter trial requirements and a halted post-marketing study create data gaps, potentially delaying full approval for adults 50-64 until late 2026.

The path to full regulatory approval for BioNTech's COVID-19 vaccine in a crucial adult demographic has grown more complex. A pivotal post-marketing study has been discontinued, a key regulator is departing, and an upcoming advisory committee meeting may now lack the necessary data for a positive recommendation, potentially pushing a decision into late 2026.

Study Discontinuation Creates Data Gap

Pfizer and BioNTech have halted a post-marketing study for their Comirnaty vaccine that was mandated by the U.S. Food and Drug Administration (FDA). The companies cited insufficient participant enrollment as the reason, explicitly ruling out safety concerns as a factor. The study, which aimed to recruit between 25,000 and 30,000 subjects, failed to meet its target, partly due to a mild COVID-19 season.

This development creates a significant data vacuum at a critical juncture. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is scheduled to meet in May to formulate recommendations for the fall 2024 vaccination campaign. Former FDA chief scientist Jesse Goodman noted that without the requisite study data, a presentation to the committee is unlikely—and without that presentation, authorization for the 50-to-64-year-old age group will not be granted.

The core issue stems from stricter FDA requirements implemented for vaccine approvals in the 50-64 demographic, which now demand large-scale, placebo-controlled trials. As a result, no COVID-19 vaccine, including Comirnaty and Moderna's Spikevax, has obtained full licensure for this group. Current approvals are limited to individuals aged 65 and older, as well as younger high-risk patients.

Leadership Shift Amid Evolving Regulatory Landscape

Compounding the situation, Vinay Prasad, head of the FDA’s vaccine office, is leaving the agency this month. Prasad was instrumental in instituting the more rigorous trial requirements for healthy adults and children, thereby reshaping the regulatory framework for the entire industry. FDA Commissioner Marty Makary announced plans to name a successor prior to Prasad's departure—a move that may offer biotech investors a degree of planning certainty following a period of unpredictable regulatory practice.

Structurally, challenges persist for vaccine developers. Declining infection rates and waning interest in booster shots are not only hampering clinical trial recruitment but also fundamentally pressuring the commercial outlook for COVID-19 vaccines.

Oncology Pipeline Offers Strategic Counterbalance

For the full 2026 fiscal year, BioNTech anticipates revenues between €2.0 billion and €2.3 billion, down from approximately €2.9 billion the previous year. Comirnaty sales are projected to decline moderately, influenced by updated vaccination recommendations and a gradual shift toward private market distribution. The company's own oncology products are not expected to contribute to revenue in 2026.

BioNTech enters this transition with substantial financial resources, holding roughly €17.2 billion in cash and securities at the end of 2025. Its strategic focus is firmly on its oncology pipeline, which currently includes nine Phase III trials, with six more slated to commence by the end of 2026.

Recent data presentations highlight progress. At the European Lung Cancer Congress in Copenhagen in late March, BioNTech shared results from its lung cancer program. The PRESERVE-003 study for gotistobart showed a 54% reduction in the risk of death compared to chemotherapy. For pumitamig, developed in collaboration with Bristol-Myers Squibb, a Chinese study reported a confirmed overall response rate of 82% and a median overall survival of 16.85 months. Analysis firm H.C. Wainwright viewed the Phase 2 outcomes positively.

Whether these advances in oncology can scale rapidly enough to offset the decline in vaccine revenue remains the central question for BioNTech's investment thesis in the coming quarters. This is particularly pertinent as the Comirnaty authorization gap for 50-to-64-year-olds is now set to remain open until at least the fall of 2026.